Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CNTO 136 in Active Lupus Nephritis
2010-020968-38Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Nov 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of siltuximab in lupus nephritis (LN) (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Percent reduction from baseline in proteinuria at Week 24. Started Nov 2010; status: completed.
02
Drugs
siltuximab
03
Conditions
lupus nephritis (LN)
Beyond the preview
Go deeper on 2010-020968-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-020968-38.